Alzheimer’s Dementia and Longevity: H2 Global Group Offers Solutions, Opens an Investment Window, and Moves Toward the Medicine of the Future
Below is a faithful, professional English translation of the full text, suitable for PR, investor materials, media publication, or international partners. The tone is formal, clear, and consistent with MedTech and HealthTech communication.
Alzheimer’s Dementia and Longevity: H2 Global Group Offers Solutions, Opens an Investment Window, and Moves Toward the Medicine of the Future
Prague, December 19, 2025 (PROTEXT) – Dementia and Alzheimer’s disease are rapidly becoming some of the greatest health, social, and economic challenges of our time—especially for the decades ahead. Alzheimer’s dementia is often referred to as the “cancer of the mind.” In its early stages, it does not progress dramatically from day to day, but instead slowly and insidiously takes away a person’s memory, identity, and independence. The consequences affect not only patients, but also their families, healthcare systems, and public budgets.
According to data from the World Health Organization, approximately 57 million people worldwide were living with dementia in 2021, with nearly 10 million new cases each year. Alzheimer’s disease accounts for roughly 60–70% of all dementia cases. At the same time, the economic burden is rising sharply. Alzheimer’s Disease International estimates that global dementia-related costs already exceed USD 1.3 trillion annually and could reach USD 2.8 trillion per year by 2030. This is a challenge that affects virtually every country—and therefore all of us.
It is precisely here that the issue of dementia intersects with the phenomenon of longevity. The desire to live longer alone is not enough. True longevity means extending the period of life spent in good health, and above all preserving a young mind—memory, concentration, and the ability to make independent decisions. At this point, preventive longevity practices naturally connect with one of the greatest medical challenges of our time.
This is where the Czech group H2 Global Group enters the picture, building a hydrogen-based platform that connects longevity with medicine.
“We are not a pharmaceutical giant with unlimited resources. We have a unique, patent-protected, and scalable approach that brings new possibilities into medicine—an approach that has already attracted the attention of global players. We deliberately chose a financing path that also allows smaller investors to participate in the growth of the project’s value ahead of key clinical milestones,” says David Maršálek, founder and CEO of H2 Global Group.
The Longevity Boom: One of the Largest Market Opportunities of Our Time
The longevity market is currently experiencing an unprecedented investment boom. Estimates suggest that the global longevity market could reach USD 1.87 trillion by 2034. Investors are directing capital into premium longevity and medical centers, biotechnology focused on aging processes, and concierge medicine—high-end private healthcare services. What successful projects share is a combination of clinical credibility, measurable and visible outcomes, and a scalable business model. H2 Global Group is building its hydrogen business precisely on this logic—as a bridge between the rapidly growing longevity market, conventional medicine, and ultimately the medicine of the future.
H2 Longevity as a New Standard: Prevention, Performance, and Healthy Aging
The concept of longevity represents a shift in how individuals, clinics, and service providers approach health. Instead of “putting out fires,” the focus is moving toward long-term vitality, regeneration, resilience, and overall quality of life. H2 Global Group has translated this trend into practice by developing a scalable model for both end customers and B2B partners, integrating molecular hydrogen technologies and know-how for safe and effective real-world use. Today, the company’s clients include elite athletes and sports clubs, spa and rehabilitation facilities, private clinics including dental practices, as well as wellness hotels and biohacking centers focused on longevity and regeneration.
H2 Longevity® Lifestyle Ostrava: A New-Generation Center Beyond Prevention
One of the most visible milestones of the year was the opening of H2 Longevity® Ostrava, publicly presented as a next-generation healthy longevity center and a model showroom for customers, distributors, professional partners, and investors.
The center combines modern longevity concepts such as molecular hydrogen inhalation using H2 Medical Technologies devices, light therapy, hydrogen hydration in the form of H2 Premium® Hydrogen Water, specialized supplements such as H2 Brain® and H2 Forte®, unique hydrogen-based cosmetics, and education focused on regeneration and healthy aging. The Ostrava center thus serves not only as a premium destination for clients, but also as a reference point for future expansion through partners.
From Longevity to the Medicine of the Future Through an Approved Clinical Study
A key step is the transition from prevention to data-driven medicine. Through its MedTech division, H2 Medical Technologies, H2 Global Group announced that the Czech State Institute for Drug Control (SÚKL) has approved the first clinical study in the Czech Republic evaluating the safety of molecular hydrogen inhalation in patients with mild cognitive impairment (MCI)—a condition often considered a precursor to Alzheimer’s dementia.
The study will use the first functional prototype of a molecular hydrogen-generating medical device developed by H2 Medical Technologies. It will begin in January 2026, run for six months, and involve approximately 30 patients aged 50–80, followed by a monitoring and data evaluation phase. Recruitment is still open.
Building on this approved clinical study, the group’s next strategic ambition is the registration of the world’s first medical device utilizing molecular hydrogen. Initial focus is on Alzheimer’s dementia (both prevention and supportive treatment), with potential expansion into other indications such as type 2 diabetes, visual and hearing disorders, dermatological conditions, and more. This modularity is crucial for the partner ecosystem, allowing clinics and longevity service providers to gradually expand their offerings—from regeneration and vitality to specialized complementary protocols.
Call for Participation in the Clinical Study
H2 Medical Technologies has issued a public call for volunteers who wish to participate and meet the following criteria:
-
age 50–80 years,
-
overall good health,
-
diagnosis of mild cognitive impairment or mild to moderate dementia,
-
preferably residence in Ostrava or the surrounding area, where the study will take place.
Participation does not guarantee any health benefit and should not be considered a substitute for standard medical treatment. Interested individuals may apply until January 19, 2026, at: david.skoloudik@H2medical.com
A Patent That Transforms a Molecule into a Platform
H2 Global Group continues to build its intellectual property portfolio. Following earlier patents, it has now been granted the European patent EP3701956B1, titled “Prophylactic or Therapeutic Agent for Dementia”, authored by Japanese professor Shigeo Ohta and his team, with H2 Global Group as the patent holder. The patent describes the use of molecular hydrogen in neurodegenerative diseases, including dementia, and is currently being extended to additional global territories.
From an investment perspective, the key value lies in the combination of scientific foundations, patent protection, a clear regulatory roadmap, and clinical data, transforming a “simple molecule” into a scalable technological platform.
Toward Regulated Medicine: Clinical Data, Safety, and Responsibility
Scientific leadership toward regulated medicine is overseen by PharmDr. Milan Krajíček, Director of Research and Development at H2 Medical Technologies.
“Our solution represents a completely new, non-invasive, and safe method, the effects of which on neurodegenerative diseases are now being clinically tested,” he says. Launching a clinical study directly linked to Professor Ohta’s patent is both an honor and a responsibility. For investors and clinics alike, it signals that this is not a marketing story, but a medically grounded project based on data.
Safety remains paramount. Prof. MUDr. David Školoudík, Ph.D., neurologist and medical lead of the study, notes: “The device produces hydrogen at a relatively low and safe concentration.”
From a Personal Story to Global Ambition
David Maršálek’s years of hands-on experience and studies at Dublin Business School are now being translated into building an international technology platform in longevity and modern medicine. Fourteen years ago, he met Professor Dušan Miljkovič in the United States—his first mentor and the scientist who introduced the world’s first hydrogen dietary supplement. That moment launched a journey that has evolved into a project with global ambitions.
Over time, Maršálek assembled a multidisciplinary team including Professor Shigeo Ohta (Japan), the Palacký University team led by Assoc. Prof. Michal Botek, PharmDr. Milan Krajíček, MUDr. Pavel Malovič, PhD., MPH, and others. The result is the creation of H2 Global Group and H2 Medical Technologies, now focused on research and development of molecular hydrogen in medicine.
Virtual Reality and Molecular Hydrogen: A Globally Unique Ecosystem
H2 Global Group has expanded its ecosystem into rehabilitation and psychology through a 20% equity stake in VR LIFE / VR Vitalis. This project is among the most advanced digital rehabilitation systems in Europe. Since H2 Global Group’s entry, the number of therapeutic modules has grown from 22 to 52, the solution has obtained MDR medical device certification, and it is actively used in clinical practice across the EU. To date, more than 63,000 therapeutic sessions have been delivered via the VR Vitalis platform.
What makes this project unique is the integration of regulated VR rehabilitation with molecular hydrogen inhalation, protected by a utility model and patent application. This combination enables simultaneous work with attention, psychological calming, guided breathing, and physiological processes related to cellular regeneration, including in the brain.
An Investment Window Before Key Milestones
In MedTech, company value typically increases in steps, not gradually—at moments such as clinical trial initiation, data readouts, or successful regulatory achievements. These milestones often transform a project into a strategic asset sought by global players.
H2 Global Group openly communicates its ambition to register the world’s first medical device using molecular hydrogen, enabling reimbursement and broad accessibility, followed by expansion into additional indications. Major MedTech acquisitions—such as Medtronic–Covidien (USD 43B), Abbott–St. Jude Medical (USD 25B), or Johnson & Johnson–Abiomed (USD 17B)—demonstrate how extraordinary value is created when clinical data, regulatory credibility, scalability, and market position converge.
This is precisely the phase in which H2 Global Group is currently operating—opening an attractive entry point for investors ahead of key clinical and regulatory milestones.
A Strategic Invitation to Investors and Partners
H2 Global Group stands at the intersection of several powerful global trends: the rapid growth of the longevity economy, the escalating burden of dementia, and the urgent need for safe, measurable, and regulator-ready medical solutions. For investors and partners, this represents an opportunity comparable to historic moments in medicine, when breakthroughs led not only to scientific progress but also to the creation of entirely new industries.
“Every day, we receive new inquiries from investors and potential partners around the world who see the opportunity to expand their portfolios with our hydrogen solutions,” says David Maršálek. “That is why H2 Global Group is deliberately opening space for investors, distributors, and strategic partners who want to help shape a new standard in longevity and the medicine of the future—and to be part of this platform before its full value is reflected on the global market.”
Contact:
www.H2Global.group
www.H2invest.cz
Source: Metro.cz PROTEXT